{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:34:17Z","timestamp":1781566457036,"version":"3.54.5"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"DOI":"10.3389\/fcvm.2020.00046","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T14:53:10Z","timestamp":1585579990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension (FLASH)"],"prefix":"10.3389","volume":"7","author":[{"given":"David","family":"Spirk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Noll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Burnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rimoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Noll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Sudano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels\u2014updated overview and meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens."},{"key":"B3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1524-6175.2007.06441.x","article-title":"Improving blood pressure control rates: is there more we can do?","volume":"9","author":"Bakris","year":"2007","journal-title":"J Clin Hypertens."},{"key":"B4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1751-7176.2010.00397.x","article-title":"Combination therapy in hypertension","volume":"13","author":"Gradman","year":"2011","journal-title":"J Clin Hypertens."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials","volume":"326","author":"Law","year":"2003","journal-title":"BMJ."},{"key":"B7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1001\/archinte.1996.00440160081011","article-title":"Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy","volume":"156","author":"Epstein","year":"1996","journal-title":"Arch Intern Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1185\/030079904X3861","article-title":"The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care","volume":"20","author":"Bramlage","year":"2004","journal-title":"Curr Med Res Opin."},{"key":"B10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3109\/10641960902929420","article-title":"Safety and tolerability of fixed-dose irbesartan\/hydrochlorothiazide for rapid control of severe hypertension","volume":"31","author":"Neutel","year":"2009","journal-title":"Clin Exp Hypertens."},{"key":"B11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.jhh.1002293","article-title":"A comparison of the efficacy and safety of irbesartan\/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension","volume":"22","author":"Neutel","year":"2008","journal-title":"J Hum Hypertens."},{"key":"B12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2147\/VHRM.S7756","article-title":"Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice","volume":"5","author":"Schmieder","year":"2009","journal-title":"Vasc Health Risk Manag."},{"key":"B13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2165\/00044011-200525120-00003","article-title":"Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension: a prospective, open-label study","volume":"25","author":"Sharma","year":"2005","journal-title":"Clin Drug Investig."},{"key":"B14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1524-6175.2002.2041.x","article-title":"Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches","volume":"5","author":"Bakris","year":"2003","journal-title":"J Clin Hypertens (Greenwich)."},{"key":"B15","unstructured":"Hypertension Sso"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/08037050500340018","article-title":"Swiss hypertension and risk factor program (SHARP): cardiovascular risk factors management in patients with type 2 diabetes in Switzerland","volume":"14","author":"Pechere-Bertschi","year":"2005","journal-title":"Blood Press."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens."},{"key":"B19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/VHRM.S930","article-title":"Early detection and management of the high-risk patient with elevated blood pressure","volume":"4","author":"Sierra","year":"2008","journal-title":"Vasc Health Risk Manag."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYP.0000000000000075","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"B21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2050-6511-15-20","article-title":"Antihypertensive drug treatment changes in the general population: the colaus study","volume":"15","author":"Christe","year":"2014","journal-title":"BMC Pharmacol Toxicol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/HJR.0b013e32831e9511","article-title":"Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study","volume":"16","author":"Danon-Hersch","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.amjhyper.2006.04.006","article-title":"Medication adherence and persistence as the cornerstone of effective antihypertensive therapy","volume":"19","author":"Burnier","year":"2006","journal-title":"Am J Hypertens."},{"key":"B24","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0002-9343(02)01100-2","article-title":"Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis","volume":"112","author":"Etminan","year":"2002","journal-title":"Am J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1524-6175.2001.01136.x","article-title":"Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension","volume":"3","author":"Oparil","year":"2001","journal-title":"J Clin Hypertens."},{"key":"B26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/VHRM.S3302","article-title":"Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension","volume":"5","author":"Bramlage","year":"2009","journal-title":"Vasc Health Risk Manag."},{"key":"B27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/IBPC.S12211","article-title":"Long-term use and tolerability of irbesartan for control of hypertension","volume":"4","author":"Forni","year":"2011","journal-title":"Integr Blood Press Control."},{"key":"B28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3810\/pgm.2012.03.2535","article-title":"The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications","volume":"124","author":"Greathouse","year":"2012","journal-title":"Postgrad Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcvm.2020.00046\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T14:53:13Z","timestamp":1585579993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcvm.2020.00046\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":28,"alternative-id":["10.3389\/fcvm.2020.00046"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2020.00046","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]},"article-number":"46"}}